Psychiatric NP Scope of Practice for Narcolepsy in Pennsylvania

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re probably asking: Can I legally prescribe stimulants and other controlled substances remotely? The short answer in 2026: yes, but it’s complicated — and the rules vary dramatically by state.

Narcolepsy treatment often requires Schedule II stimulants (Adderall, Ritalin), Schedule IV wakefulness agents (modafinil), and even Schedule III drugs like sodium oxybate. Under normal federal law (the Ryan Haight Act), you’d need at least one in-person visit before prescribing any controlled substance via telemedicine. But here’s the reality: federal COVID-era telehealth flexibilities remain extended through December 31, 2026, allowing you to initiate and manage these medications remotely without an in-person exam — as long as you follow DEA requirements and state law.

That last part is critical: state law. While the DEA gives you temporary permission, states like Florida effectively ban remote prescribing of Schedule II stimulants for narcolepsy (they only allow it for psychiatric disorders), and states like Texas prohibit PMHNPs from prescribing Schedule II drugs in outpatient settings at all. Meanwhile, New York, California, and Illinois are far more permissive — especially for experienced, independent NPs.

Let’s break down what you actually need to know to practice legally and build a sustainable narcolepsy telehealth practice.

Federal Law: The DEA’s Temporary Green Light (and What Comes Next)

The Ryan Haight Act’s In-Person Requirement

The Ryan Haight Online Pharmacy Act (2008) normally requires practitioners to conduct at least one in-person medical evaluation before prescribing controlled substances via telemedicine. There are narrow exceptions — like if the patient is in a DEA-registered hospital, or if another physician who examined the patient in person referred them to you — but for most telehealth practices, these don’t apply.

What this means for narcolepsy: Without the current federal waiver, you couldn’t start a new patient on Adderall or modafinil remotely. You’d need to see them face-to-face at least once, or coordinate with a local provider who did.

COVID-Era Flexibilities (Extended Through 2026)

In March 2020, the DEA waived the in-person requirement due to the public health emergency. Even after the PHE ended in May 2023, the DEA (with HHS) has repeatedly extended these telehealth flexibilities. As of January 2026, the extension runs through December 31, 2026 — giving providers a stable 12-month window to prescribe controlled substances via telehealth without an initial in-person visit, as long as you meet standard prescribing requirements (state licensure, DEA registration, legitimate medical purpose).

What you can do right now:

• Evaluate a narcolepsy patient via video (or in some cases audio-only if state law allows)
• Diagnose narcolepsy based on history, symptoms, and coordinating diagnostic testing (polysomnography, MSLT — typically arranged with a local sleep lab)
• Prescribe Schedule II stimulants, Schedule IV modafinil, or Schedule III sodium oxybate (if you’re enrolled in the Xyrem REMS program)
• Manage ongoing medication adjustments and refills remotely

The catch: This is temporary. The DEA is working on permanent telemedicine rules. Early proposals (2023) suggested requiring an in-person visit after an initial 30-day supply or banning telehealth initiation of Schedule II stimulants entirely. Massive pushback (over 38,000 public comments) forced the DEA to reconsider. Final rules will likely land somewhere between full flexibility and strict in-person requirements — possibly allowing telemedicine prescribing for established diagnoses like narcolepsy with defined safeguards (e.g., initial supply limits, follow-up requirements).

Bottom line: Until the DEA finalizes new rules, you’re operating under the extension. But you should plan ahead: consider hybrid models (partnering with local clinics for required in-person visits or diagnostic testing), maintain meticulous documentation, and stay informed through DEA announcements and professional organizations.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where You Can (and Can’t) Prescribe for Narcolepsy

Florida: The Problem State for Narcolepsy Telehealth

Florida’s telehealth statute explicitly prohibits prescribing Schedule II controlled substances via telemedicine — with four exceptions: treating a psychiatric disorder, inpatient hospital care, hospice, or nursing home residents.

The narcolepsy problem: Narcolepsy is a neurological sleep disorder, not a psychiatric condition. Even though you’re a psychiatrist or PMHNP, prescribing Adderall for narcolepsy doesn’t fall under the ‘psychiatric disorder’ exception. You cannot legally prescribe Schedule II stimulants for narcolepsy via telehealth in Florida under current state law.

Workarounds:

• Use modafinil or armodafinil (Schedule IV) — these aren’t banned via telehealth
• Require at least one in-person visit with you or a collaborating provider to start stimulants, then manage follow-ups remotely
• Partner with Florida-based physicians who can handle the stimulant prescriptions while you manage other aspects of care

PMHNP considerations: Florida also limits APRNs to 7-day supplies of Schedule II drugs (unless you’re a designated ‘psychiatric nurse’ treating a mental illness). Even with that exemption, narcolepsy wouldn’t qualify. You’d need an MD to handle stimulant prescriptions for any meaningful duration.

Citation: Florida Statute §456.47 explicitly restricts Schedule II/III teleprescribing except for listed exceptions.

Texas: PMHNPs Can’t Prescribe Schedule II — At All

Texas law is crystal clear: APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings. The only exceptions are inpatient hospital admissions (≥24 hours), emergency departments, or terminally ill hospice patients — and even then, the prescription must be filled at the facility pharmacy.

What this means:

• Psychiatrists in Texas can prescribe narcolepsy stimulants via telehealth (using video, as required by Texas law) under the current DEA waiver
• PMHNPs in Texas can prescribe modafinil (Schedule IV) under a physician delegation agreement, but cannot prescribe Adderall, Ritalin, or any Schedule II drug for narcolepsy patients in outpatient care

Practical reality: If you’re a PMHNP-led practice or platform in Texas, you need psychiatrists on staff to handle Schedule II prescriptions. Alternatively, you focus on modafinil-responsive patients (many narcolepsy patients do well on Schedule IV agents alone).

Telehealth requirements: Texas mandates two-way audio-visual communication (live video) for any controlled substance prescribing. A phone call alone won’t meet the standard. You must also check the Texas Prescription Monitoring Program (PMP) before prescribing.

New York: Full Flexibility (If You Follow Federal Law)

New York finalized telehealth controlled substance rules in May 2025 that essentially defer to federal law. The state requires an in-person exam before prescribing controlled substances unless you meet specific exceptions — one of which is complying with applicable federal DEA regulations.

What this means now: Under the current DEA waiver (through 2026), you can prescribe narcolepsy medications via telehealth without an in-person visit. When federal rules tighten, New York’s requirement will automatically kick in — but the state built in flexibility for providers who follow DEA-compliant telemedicine exceptions.

PMHNP scope: New York is a full practice state for experienced NPs (≥3,600 hours). As of 2022, the collaboration requirement expired permanently. An independent PMHNP in New York can:

• Diagnose narcolepsy
• Order diagnostic testing (coordinate with local sleep labs)
• Prescribe Schedule II-V medications independently (with DEA registration and state narcotics certificate)
• Manage the full scope of narcolepsy treatment via telehealth

Requirements: You must check New York’s I-STOP prescription monitoring program before each controlled substance prescription and use electronic prescribing (mandatory).

Citation: New York’s 2025 rule aligns state telehealth prescribing with federal DEA standards, explicitly allowing teleprescribing when federal law permits it.

California: NP Independence is Here (But With Prerequisites)

California recently implemented full practice authority for NPs via AB 890, though with conditions. As of 2023, NPs with ≥4,600 hours (roughly 3 years) of supervised practice can practice independently, including prescribing Schedule II-V controlled substances.

What you need:

• Complete required pharmacology education on controlled substances (including addiction risk)
• Obtain a California Board of Registered Nursing furnishing number with Schedule II authority
• Get a DEA registration

Telehealth: California has no state-imposed in-person exam requirement for controlled substances via telehealth — it follows federal law. A thorough video exam meets the standard of care.

Practical considerations:

• You must check California’s CURES prescription drug monitoring program before prescribing Schedule II-IV drugs (initially and at least every 4 months for ongoing therapy)
• E-prescribing is mandatory
• Independent NPs can handle the full narcolepsy care continuum, though coordinating diagnostic sleep studies with local labs is still necessary (narcolepsy diagnosis typically requires polysomnography and MSLT)

Bottom line: California is increasingly NP-friendly for narcolepsy telehealth. Experienced PMHNPs can build independent practices; newer NPs still need physician oversight via standardized procedures.

Illinois: Full Practice Authority (With Some Caveats)

Illinois grants full practice authority to NPs after 4,000 hours of collaborative practice plus 250 hours of continuing education. Once you achieve FPA status, you can prescribe Schedule II-V independently — though Illinois requires a Mid-Level Practitioner Controlled Substance License in addition to your DEA registration.

The consultation requirement: Illinois law mandates that NPs with FPA maintain a ‘consultation relationship’ with a physician when prescribing benzodiazepines or opioids. Stimulants (Schedule II but not opioids) likely don’t trigger this requirement, meaning FPA-NPs can prescribe Adderall or methylphenidate for narcolepsy independently.

Telehealth: Illinois has no specific prohibition on controlled substance teleprescribing beyond federal requirements. A proper video exam satisfies the standard of care.

Requirements:

• Check the Illinois Prescription Monitoring Program (ILPMP) before prescribing
• Use electronic prescribing (mandatory since January 2023)
• Document clinical rationale thoroughly

For less experienced NPs: If you haven’t achieved FPA, you need a physician collaborative agreement that explicitly delegates Schedule II prescribing authority for narcolepsy medications. Most collaborating physicians in Illinois do delegate this, but it must be specified in your agreement.

Pennsylvania: Collaboration Required, With Limits

Pennsylvania is a restricted practice state for NPs. All CRNPs (Certified Registered Nurse Practitioners) must have a collaborative agreement with a physician.

Prescribing limits:

• CRNPs can prescribe Schedule II drugs, but only 30-day supplies initially
• Any continuation beyond 30 days requires physician consultation and patient re-evaluation
• Schedule III-IV drugs limited to 90-day supplies

Telehealth: Pennsylvania has no specific state ban on controlled substance teleprescribing — it follows federal law. You can establish a patient relationship via video and prescribe accordingly.

Practical reality: If you’re a PMHNP treating narcolepsy in Pennsylvania, you’ll need physician involvement for:

• Periodic review (at least monthly for ongoing Schedule II therapy)
• Any dose escalations or changes in stimulant type
• Coordinating diagnostic testing (since narcolepsy diagnosis typically requires in-person sleep studies)

For psychiatrists: No special restrictions beyond federal requirements. Pennsylvania is part of the Interstate Medical Licensure Compact (IMLC), which can streamline obtaining licenses in other IMLC states.

Psychiatrist vs PMHNP: Who Can Treat Narcolepsy?

Psychiatrists (MD/DO):

✅ Full authority to diagnose and treat narcolepsy in all 50 states
✅ Can prescribe Schedule II-V medications independently (with DEA registration)
✅ No scope-of-practice limitations
⚠️ Must still follow state telehealth laws and PDMP requirements

The reality check: While you can treat narcolepsy, you should be competent to do so. Narcolepsy is typically a sleep medicine specialty, often managed by neurologists. Many psychiatric providers encounter it (especially the overlap with ADHD, depression, and medication side effects), but you should:

• Stay current on diagnostic criteria (ICSD-3 standards)
• Understand when to refer for specialized testing (polysomnography, MSLT, CSF hypocretin testing)
• Know combination therapies (stimulants + sodium oxybate for cataplexy, SSRIs/SNRIs for cataplexy and sleep paralysis)
• Consider consulting or co-managing complex cases with sleep specialists

PMHNPs:

✅ Can diagnose and treat narcolepsy in most states (within competency)
❌ Cannot prescribe Schedule II stimulants in Texas or Georgia (outpatient settings)
⚠️ Limited to 7-day Schedule II supplies in Florida (unless treating psychiatric disorders)
✅ Full authority in New York, California (with experience), and Illinois (with FPA)
⚠️ Need physician collaboration in Pennsylvania (with 30-day Schedule II limits)

The competency question: You’re legally allowed to manage narcolepsy in most states, but should you? If you’re a PMHNP with sleep medicine training or significant experience with stimulant management (e.g., ADHD treatment), narcolepsy is a reasonable extension of your practice. If not, consider:

• Taking continuing education in sleep disorders
• Establishing referral relationships with sleep specialists for diagnostic confirmation
• Co-managing cases (you handle medications, neurologist handles diagnosis and complex cataplexy management)

Malpractice considerations: Your malpractice insurance should cover psychiatric care. Treating narcolepsy (a neurological condition) may raise questions if challenged, but the overlap with psychiatric medications (stimulants, antidepressants) and mental health comorbidities (depression, anxiety are common in narcolepsy) generally keeps it within scope. Document your competency and rationale clearly.

The Economics: Why Platforms Like Klarity Make Sense for Narcolepsy Care

Here’s the uncomfortable truth about DIY marketing for narcolepsy patients: acquiring a qualified psychiatric patient through traditional marketing costs $200-500+ per patient when you factor in all real costs:

• SEO: 6-12 months of investment ($2,000-5,000/month for content, technical optimization, link building) before generating meaningful patient flow. Most solo providers don’t have the expertise or budget for this sustained effort.

• Google Ads: Mental health keywords cost $15-40+ per click. With typical conversion rates (2-5% from click to booked appointment after accounting for no-shows and unqualified leads), you’re looking at $200-400+ per booked patient — and that’s if you optimize campaigns well.

• Directory listings (Psychology Today, Zocdoc): Monthly subscription fees ($30-100+) plus competition with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+ per new patient) on top of subscription costs. Total monthly spend easily hits $500-1,500 with uncertain ROI.

• Hidden costs: Staff time to handle and qualify leads, no-show rates from cold leads (30-40% typical), failed campaigns, agency/consultant fees if you outsource.

The alternative: Pay-per-appointment models (like Klarity Health) eliminate the upfront risk entirely. You pay a standard fee only when a qualified, pre-matched patient books with you. No wasted ad spend. No monthly subscriptions sitting idle. No gambling on SEO that might not work.

For narcolepsy specifically, patient acquisition is even harder:

• Narcolepsy affects only ~1 in 2,000 people (rare condition)
• Many patients are misdiagnosed for years before finding the right specialist
• Patients often search for ‘sleep disorder’ or ‘excessive daytime sleepiness’ (not ‘narcolepsy psychiatrist’)
• Diagnostic confirmation requires coordinating sleep studies, which adds friction to the patient journey

A platform that handles patient matching, qualification, and scheduling removes these barriers. You focus on delivering care; the platform handles acquisition economics.

ROI comparison:

• DIY route: Spend $3,000-5,000/month on marketing with uncertain results, wait 6-12 months for SEO to work, handle lead qualification yourself
• Platform route: Pay per booked appointment, see patients immediately, pre-qualified leads matched to your specialty and availability

For most providers (especially those starting out or scaling), the platform model is the smart economic choice. You’re paying for guaranteed ROI instead of gambling on marketing channels you may not have expertise in.

Practical Compliance Checklist for Narcolepsy Telehealth

Before You Start:

✅ Verify state licensure in the patient’s state (for telehealth, you must be licensed where the patient is located)
✅ Obtain DEA registration with Schedule II-V authority (multi-state registration now possible with one DEA number covering all states of licensure)
✅ Check state-specific PMHNP scope if you’re an NP (can you prescribe Schedule II in this state?)
✅ Register with state PDMP (required in nearly all states before prescribing controlled substances)
✅ Set up e-prescribing system (mandatory for controlled substances in most states)
✅ Review state telehealth laws (video vs audio-only requirements, consent requirements, controlled substance restrictions)

For Each Narcolepsy Patient:

✅ Conduct thorough telehealth evaluation:

• Comprehensive sleep history (Epworth Sleepiness Scale, sleep diary)
• Screen for cataplexy, sleep paralysis, hypnagogic hallucinations
• Rule out other causes (sleep apnea, depression, medication side effects)
• Mental status exam (observable via video)
• Document clinical rationale for narcolepsy diagnosis

✅ Coordinate diagnostic testing (if not already done):

• Overnight polysomnography (rule out sleep apnea)
• Multiple Sleep Latency Test (confirms excessive daytime sleepiness and REM sleep abnormalities)
• Consider referral to local sleep lab or neurologist for testing

✅ Check state PDMP before prescribing any controlled substance (required by law in most states)

✅ Document thoroughly:

• Diagnosis with supporting clinical criteria
• Medication choice and dosing rationale
• Discussion of risks (stimulant abuse potential, cardiovascular risks, psychiatric side effects)
• Plan for follow-up and monitoring

✅ Obtain informed consent specific to telehealth (most states require this, covering privacy, technology limitations, emergency procedures)

✅ E-prescribe controlled substances (paper prescriptions generally not allowed)

✅ Schedule appropriate follow-ups:

• Initial: weekly or biweekly to titrate dose and monitor side effects
• Ongoing: monthly to quarterly once stable (may be required for Schedule II prescribing in some states)

For Sodium Oxybate (Xyrem/Xywav) Specifically:

✅ Enroll in the REMS program (FDA-mandated; required to prescribe sodium oxybate)
✅ Coordinate with certified pharmacy (Xyrem/Xywav can only be dispensed through restricted distribution program)
✅ Document severe daytime sleepiness or cataplexy (approval criteria)
✅ Screen for contraindications (alcohol use, respiratory depression risk, sleep apnea)

When Federal Rules Tighten: Plan Ahead

The current DEA extension ends December 31, 2026. While we expect the DEA to finalize more flexible rules than initially proposed (given overwhelming opposition to strict limits), you should prepare for some level of tightening:

Likely scenarios:

1. Initial supply limits: First prescription via telehealth limited to 30 days, with in-person visit required for continuation
2. Diagnosis-specific exceptions: Telehealth prescribing allowed for established diagnoses like narcolepsy with documented sleep study results
3. Special registration: DEA may introduce a telemedicine-specific registration allowing qualified clinicians to prescribe controlled substances nationwide via telehealth

How to prepare now:

✅ Build hybrid care models:

• Partner with local clinics or primary care providers for in-person exams (can be done once, then ongoing telehealth)
• Coordinate with sleep labs for diagnostic testing (establishes local care team)

✅ Document exceptional cases:

• Patients in rural areas with no local access to sleep specialists
• Patients who’ve been stable on medications for years (established diagnosis)
• Clinical rationale for telehealth (patient mobility issues, transportation barriers)

✅ Stay informed:

• Monitor DEA and HHS announcements (check dea.gov and hhs.gov regularly)
• Join professional organizations (APA, AANP) that track regulatory changes
• Subscribe to telehealth policy updates (e.g., Center for Connected Health Policy)

✅ Maintain high standards of care:

• Even with federal flexibility, document as if you were justifying every prescription
• Use validated diagnostic tools and rating scales
• Schedule regular follow-ups and monitor outcomes
• This isn’t just good medicine — it’s legal protection if rules change or you’re audited

FAQ: Narcolepsy Telehealth Prescribing

Can I prescribe Adderall for narcolepsy via telehealth in 2026?

Depends on your state. Under current federal law (DEA waiver through Dec 31, 2026), yes — if your state allows it. Psychiatrists can prescribe in all states except Florida (which bans Schedule II via telehealth for narcolepsy). PMHNPs can prescribe in New York, California (if experienced), and Illinois (with FPA), but not in Texas, Georgia, or Florida. Pennsylvania NPs need physician collaboration with 30-day limits.

Do I need an in-person visit before prescribing narcolepsy medications?

Not under current federal rules (through 2026). The DEA waiver allows telehealth initiation without an in-person exam. However, Florida state law effectively requires it for Schedule II stimulants (or you use Schedule IV modafinil instead), and New York will require it once federal flexibilities end (unless you meet specific exceptions).

What happens when the DEA waiver expires at the end of 2026?

The DEA is expected to finalize permanent telemedicine rules before or shortly after the waiver expires. Likely outcomes include initial supply limits (e.g., 30-day prescriptions via telehealth with subsequent in-person visit required) or diagnosis-specific exceptions allowing telehealth for conditions like narcolepsy with proper documentation. We’ll update this guidance as rules are finalized — check back or subscribe to regulatory updates.

Can PMHNPs diagnose narcolepsy, or do you need to be a physician?

PMHNPs can legally diagnose narcolepsy in all states (within their scope of practice and competency). Narcolepsy is a sleep disorder, not exclusively neurological, and psychiatric providers often manage it given the overlap with stimulant medications and mental health comorbidities. However, confirming the diagnosis typically requires objective testing (polysomnography, MSLT) that you’d coordinate with a sleep lab or neurologist.

How much does it cost to acquire narcolepsy patients through marketing vs. a platform?

DIY marketing: $200-500+ per qualified patient when you factor in all costs (SEO investment, Google Ads at $15-40/click, directory fees, lead qualification time, no-shows). SEO takes 6-12 months of sustained investment before generating meaningful flow.

Platform model (e.g., Klarity): Pay-per-appointment fee only when a qualified patient books. No upfront spend, no monthly subscriptions, no wasted ad budget. For rare conditions like narcolepsy, platforms that pre-qualify and match patients remove the acquisition risk entirely.

Which states are best for building a narcolepsy telehealth practice?

For psychiatrists: New York, California, Illinois, Pennsylvania, Texas (all allow telehealth prescribing under current federal rules; avoid Florida for stimulants).

For PMHNPs: New York and Illinois (full practice authority for experienced NPs), California (with NP independence pathway). Avoid Texas (can’t prescribe Schedule II outpatient), Florida (7-day limits and telehealth ban), and be cautious in Pennsylvania (physician collaboration required with 30-day Schedule II limits).

Market opportunity: All six states have underserved populations in rural and urban areas. California and Texas have the largest populations (more potential patients), but also more competition. Smaller states with NP-friendly laws (New York, Illinois) may offer better ROI for independent PMHNPs.

The Bottom Line: Narcolepsy Telehealth is Viable — If You Navigate the Rules

Right now, treating narcolepsy via telehealth is legally and economically viable for both psychiatrists and PMHNPs — but you must navigate a complex patchwork of federal and state regulations.

Key takeaways:

1. Federal law currently allows it (through Dec 2026), but state restrictions can override this (especially Florida for narcolepsy, Texas for PMHNPs)

2. PMHNP scope varies dramatically by state — full authority in NY/IL/CA (with experience), severe restrictions in TX/FL

3. The economics favor platforms that handle patient acquisition, especially for rare conditions like narcolepsy where DIY marketing is expensive and time-consuming

4. Plan for rule changes by building hybrid care models (partnering with local providers for required in-person visits or diagnostic testing) and maintaining exceptional documentation

5. Stay current — regulations are evolving rapidly. What’s legal today may require adjustments in 2027 when the DEA finalizes new rules.

If you’re a psychiatrist or PMHNP looking to expand into narcolepsy care, now is the time to act while federal flexibilities are in place. Joining a platform like Klarity Health eliminates the patient acquisition headache, ensures compliance support, and lets you focus on what you do best: providing expert care to underserved patients who desperately need it.

Ready to see qualified narcolepsy patients without the marketing gamble? Explore how Klarity Health’s pay-per-appointment model can grow your practice with zero upfront risk. You control your schedule, your rates, and your scope — we handle everything else.

Citations and References

1. U.S. Department of Health & Human Services. (January 2, 2026). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. Press Release. Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (November 15, 2024). DEA and HHS Extend Telemedicine Flexibilities Through 2025. DEA Announcement. Retrieved from https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

3. U.S. Drug Enforcement Administration. (December 31, 2025). DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care. Press Release. Retrieved from https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care

4. 21 U.S. Code §829(e) – Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Legal Information Institute, Cornell Law School. Retrieved from https://www.law.cornell.edu/definitions/uscode.php?def_id=21-USC-1796173870-113781527

5. Nixon Peabody LLP. (June 18, 2025). New York State Finalizes Telemedicine Rule for Controlled Substances. Healthcare Alert. Retrieved from https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206